Stock of Zevra Therapeutics, Inc. (ZVRA) is climbing roughly 19 percent on Tuesday morning trading after GeneDx announced a new genetic testing program with Zevra to expand access to exome sequencing to help clinicians confirm diagnosis and guide clinical decision-making in Niemann-Pick Disease type C.
The company's shares are currently trading at $10.83 on the Nasdaq, up 18.75 percent. The stock opened at $9.12 and has climbed as high as $11.40 so far in today's session. Over the past year, it has traded in a range of $6.19 to $13.16.
Through this program, eligible patients in the United States will have access to genomic testing via GeneDx to help confirm or rule out a diagnosis of NPC.
For comments and feedback contact: editorial@rttnews.com
Economic News
What parts of the world are seeing the best (and worst) economic performances lately? Click here to check out our Econ Scorecard and find out! See up-to-the-moment rankings for the best and worst performers in GDP, unemployment rate, inflation and much more.
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.